Can statins pass the aspirin litmus test in cancer?

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3395-3396

  Kauh, John ^a   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONAFARNIB; MEVALONIC ACID; PLACEBO; RALOXIFENE; TAMOXIFEN; TIPIFARNIB;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COLON POLYP; COLORECTAL CANCER; EDITORIAL; HEADACHE; HUMAN; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; ANTICARCINOGENIC AGENTS; ASPIRIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MICE; RANDOMIZED CONTROLLED TRIALS;

EID: 34548147272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9511     Document Type: Editorial

References (17)

1. Narisawa T, Fukaura Y, Tanida N, et al: Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine- induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 180:131-138, 1996
2. Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352:2184-2192, 2005
3. Friis S, Poulsen AH, Johnsen SP, et al: Cancer risk among statin users: A population-based cohort study. Int J Cancer 114:643-647, 2005
4. Setoguchi S, Glynn RJ, Avorn J, et al: Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115:27-33, 2007
5. Coogan PF, Smith J, Rosenberg L: Statin use and risk of colorectal cancer. J Natl Cancer Inst 99:32-40, 2007
6. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635-637, 2004
7. Blais L, Desgagne A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 160:2363-2368, 2000
8. Strandberg TE, Pyorala K, Cook TJ, et al: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777, 2004
9. Bonovas S, Filioussi K, Tsavaris N, et al: Statins and cancer risk: A literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24:4808-4817, 2006
10. Bonovas S, Filioussi K, Flordellis CS, et al: Statins and the risk of colorectal cancer: A meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 25:3462-3468, 2007
11. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting - Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012, 2000
12. Moher D, Cook DJ, Eastwood S, et al: Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement - Quality of Reporting of Meta-Analyses. Lancet 354:1896-1900, 1999
13. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884, 2006
14. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885-895, 2006
15. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
16. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
17. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003